Edition:
India

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

84.51EUR
18 Oct 2017
Change (% chg)

-- (--)
Prev Close
€84.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,145,571
52-wk High
€92.97
52-wk Low
€67.22

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €108,903.00
Shares Outstanding(Mil.): 1,262.50
Dividend: 2.96
Yield (%): 3.43

Financials

  Industry Sector
P/E (TTM): -- 30.44 16.24
EPS (TTM): -- -- --
ROI: -- 14.17 10.90
ROE: -- 15.52 14.09

Regeneron-Sanofi drug succeeds mid-stage study

Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat inflammation in the esophagus, mainly caused by food allergies, met the main goal of a mid-stage study.

17 Oct 2017

CORRECTED-UPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study

Oct 16 Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat inflammation in the esophagus, mainly caused by food allergies, met the main goal of a mid-stage study.

17 Oct 2017

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

16 Oct 2017

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Oct 16 Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

16 Oct 2017

Regeneron-Sanofi throat infection drug succeeds key study

Oct 16 Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat patients with a rare throat infection met the main goal of a mid-stage study.

16 Oct 2017

BRIEF-Aimmune Therapeutics collaborates to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

* Aimmune Therapeutics announces clinical collaboration to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

16 Oct 2017

BRIEF-Regeneron and Sanofi announce positive phase 2 study results for dupilumab

* REGENERON AND SANOFI ANNOUNCE POSITIVE PHASE 2 STUDY RESULTS FOR DUPILUMAB IN PATIENTS WITH ACTIVE MODERATE-TO-SEVERE EOSINOPHILIC ESOPHAGITIS

16 Oct 2017

Sanofi boosts vaccines business with 170 million euro investment

VAL-DE-REUIL, France Sanofi on Thursday expressed confidence in the growth of its influenza vaccines after committing to invest 170 million euros to expand its manufacturing facility at Val-de-Reuil in north-western France.

12 Oct 2017

UPDATE 1-Sanofi boosts vaccines business with 170 mln euro investment

* Points to risk of over-optimism over universal flu vaccine (Adds quotes, details)

12 Oct 2017

French and Benelux stocks-Factors to watch on October 12

Oct 12 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.

12 Oct 2017

Earnings vs. Estimates